Interested in a collaboration?
Contact us to discuss the possibilities.
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/
Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...
Contact us to discuss the possibilities.